Chlamydia pneumoniae and atherosclerosis

Seminars in Respiratory Infections

Volumn 18, Issue 1, 2003, Pages 48-54

  Campbell, Lee Ann ^a   Kuo, Cho Chou ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; MACROLIDE; PLACEBO;

ANIMAL CELL; ANIMAL MODEL; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FOAM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; MACROPHAGE; MAJOR CLINICAL STUDY; MONOCYTE; MOUSE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; MICE; RABBITS;

EID: 0037352293     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/srin.2003.50006     Document Type: Review

References (47)

1. Grayston JT: Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 181:S402-S410, 2000 (suppl 3)
2. Grayston JT, Aldous MB, Easton A, et al: Evidence that Chlamydia pneumonia strain TWAR, causes pneumonia and bronchitis. J Infect Dis 168:1231-1235, 1993
3. Campbell LA, Kuo C-C, Grayston JT: Current knowledge on the association of Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis 4:571-579, 1998
4. Dowell SF, Peeling RW, Boman J, et al: Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA), and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 33:492-502, 2001
5. Saikku P, Mattila K, Nieminen RS, et al: Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2:983-996, 1988
6. Linnanmäki E, Leinonen M, Mattila K, et al: Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 87:1130-1134, 1993
7. O'Connor, Taylor C, Campbell LA, et al: Potential infectious etiologies of atherosclerosis: A multifactorial perspective. Emerg Infect Dis 7:780-788, 2001
8. Shor A, Kuo C-C, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 82:158-161, 1992
9. Kuo C-C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissue. J Infect Dis 181:S516-S518, 2000 (suppl 3)
10. Jackson LA, Campbell LA, Kuo C-C, et al: Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 176:292-295, 1997
11. Ramirez J, Ahkee A, Ganzel BL, et al: Isolation of Chlamydia pneumoniae (C pn) from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 125:979-982, 1996
12. Maass M, Bartels C, Engel PM, et al: Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 31:827-832, 1998
13. Jackson LA, Campbell LA, Schmidt RA, et al: Specificity of detection of Chlamydia pneumoniae in cardiovascular and non-cardiovascular tissues: Evaluation of the innocent bystander hypothesis. Am J Pathol 150:1785-1790, 1997
14. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126, 1998
15. Godzik K, O'Brien ER, Wang S-W, et al: In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 33:2411-2414, 1995
16. Gaydos CA, Summersgill JT, Sahney NN, et al: Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells and aortic artery smooth muscle cells. Infect Immun 64:1614-1620, 1996
17. Haranaga S, Yamaguchi H, Friednam H, et al: Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro. Infect Immun 69:7753-7759, 2001
18. Boman J, Söderberg S, Forsberg J, et al: High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 178:274-277, 1998
19. Maass M, Jahn J, Gieffers J, et al: Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis 181:S449-S551, 2000 (suppl 3)
20. Moazed TC, Kuo CC, Grayston JT, et al: Systemic dissemination of C. pneumoniae infection via macrophages. J Infect Dis 177:132-135, 1998
21. Kaul R, Uphoff J, Wiedeman J, et al: Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation 102:2341-2346, 2000
22. Lin T-M, Campbell LA, Rosenfeld MR, et al: Identification of a human monocyte derived factor that enhances the growth of Chlamydia pneumoniae in human arterial endothelial cells. J Infect Dis 183:1368-1372, 2001
23. Kalayoglu M, Perkins P, Byrne GI: Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microb Infect 2:963-969, 2001
24. Mahony J, Coombes B: Chlamydia pneumoniae and atherosclerosis: Does the evidence support a causal or contributory role. FEMS Microbiol Lett 197:1-9, 2001
25. Kalayoglu MV, Indrawati Morrison RP, et al: Chlamydial virulence determinants inatherogenesis: The role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 181: S483-S489, 2000 (suppl 3)
26. Kol A, Bourcier T, Lichtman AH, et al: Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 103:571-577, 1999
27. Fong IW, Chiu B, Viira E, et al: Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 35: 48-52, 1997
28. Laitinen K, Laurila A, Pyhälä L, et al: Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 65:4832-4835, 1997
29. Fong IW, Chiu B, Viira E, et al: De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun 67:6048-6055, 1999
30. Blessing E, Lin TM, Campbell LA, et al: Chlamydia pneumoniae induces inflammatory changes in hearts and aortas of C57B1/6 mice. Infect Immun 68:4765-4868, 2000
31. Caligiuri G, Rottenberg M, Nicoletti A, et al: Chlamydia pneumonaie infection does not induce or modify atherosclerosis in mice. Circulation 103:2834-2838, 2001
32. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 103:747-753, 1999
33. Moazed TC, Kuo C-C, Grayston JT, et al: Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 175:883-890, 1997
34. Muhlestein JB, Anderson JL, Hammond EH, et al: Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97:633-636, 1998
35. Moazed TC, Campbell LA, Rosenfeld ME, et al: Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in ApoE-deficient mice. J Infect Dis 180:238-241, 1999
36. Burnett MS, Gaydos CA, Madico GE, et al: Atherosclerosis in apoE knockout mice infected with multiple pathogens J Infect Dis 183:226-231, 2001
37. Rothstein NM, Quinn TC, Madico G, et al: Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J Infect Dis 183:232-238, 2001
38. Aalto-Setala K, Laitinen K, Erkkila L, et al: Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21:578-584, 2001
39. Liu L, Hu H, Ji H, et al: Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. Mol Cell Biochem 215:123-128, 2000
40. Blessing E, Campbell LA, Rosenfeld M, et al: Infection with Chlamydia pneumoniae accelerates the induction and progression of atherosclerosis in diet-induced hypercholesterolemic C57BL/6J mice. In Saikku P (ed): Proceedings: Fourth Meeting of the European Society for Chlamydia Research. Helsinki, Finland, 2000, p 247
41. Fong I: Antibiotic effects in a rabbit model of Chlamydia pnenumoniae-induced atherosclerosis. J Infect Dis 181: S514-S519, 2000 (suppl 3)
42. Gupta S, Leatham EW, Carrington D, et al: Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 46:404-407, 1997
43. Gurfinkel E, Bozovich G, Beck E, et al: Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 20:121-127, 1999
44. Muhlestein JB, Anderson JL, Carlquist JF, et al: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation 102:1755-1760, 2000
45. Dunne MW: Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: The WIZARD (Weekly Intervention with Zithromax [Azithromycin] for Atherosclerosis and its Related Disorders) trial. J Infect Dis 181:S572-S578, 2000 (suppl 3)
46. Jackson LA: Description and status of the Azithromycin and Coronary Events Study (ACES). J Infect Dis 181: S579-S581, 2000 (suppl 3)
47. Rosen H, Mulestein JB, Barlett J, et al: Collaborative multidisciplinary workshop report: Clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease. J Infect Dis 181: S582-S584, 2000 (suppl 3)